settled at the bottom on standing. Hence their experimental observations might be interpreted as follows. On standing inside the incubator for over 6 h, the 131 I-Lipiodol component of the emulsion has separated and sunk. It came into intimate contact with the monolayer of cells at the bottom of the well. The local radioactivity concentrations in the vicinity of the cells were 1.0, 2.0 and 4.0 µCi of 131 I in 4 µl of 131 I-Lipiodol (equivalent to 250, 500 and 1000 µCi ml -1 for low, medium and high dose). Thus a high radiation dose was delivered to the cells. When the cells are killed or damaged by the radiation, the cells lost their integrity and the cell membrane became permeable to the passage of 131 I-Lipiodol which ended up inside the cells. The endothelial cells should have a lower population of dividing cells which are more susceptible to radiation damage and so the effects on the benign cells were seen to be sub-lethal while the malignant cells were killed. However, the integrity of the endothelial cell might still have been affected in some way and so the 131 I-Lipiodol could gain its passage into some of these benign cells.
Such radiation effects were not observed with aqueous NaI ( 131 I) solution. The aqueous NaI ( 131 I) solution, being completely miscible with the culture medium, will be distributed uniformly throughout the 100 µl of medium and therefore the effective radioactivity concentrations in the vicinity of the cells was really 40 µCi ml -1 . So even the low dose 131 I-Lipiodol was providing a 6.25 times higher local radioactivity concentration of 131 I than in the aqueous NaI ( 131 I) solution. It is therefore logical for the authors to observe no cytotoxic effect in the NaI ( 131 I) solution despite the total radioactivity in the well was four times that of the low dose 131 I-Lipiodol. We can assure the authors of a similar cell killing effect as observed with 131 I-Lipiodol if they try to increase the NaI ( 131 I) concentration to 250 µCi ml -1 . From our own experience in treating 26 patients with hepatocellular carcinoma using 131 I-Lipiodol (Leung et al, 1994) and the results of the other 12 clinical series of hepatic cancer treated with the same agent that have recently been reviewed by us (Ho et al, 1998) we agree with the authors that the response is highly variable and may partly depend on local pharmacokinetics. The other important factor of course is the radio-sensitivity of the tumour cells. As we have pointed out in our review article (Ho et al, 1998) for a lesion to be completely destroyed by 131 I-Lipiodol, it needs to uptake the agent in such a way that every cancer cell lies within 2.4 mm from the radioactive oil, which is the maximum penetration of the beta-radiation from 131 I. 131 I-Lipiodol could hardly concentrate in hypovascular or necrotic tumours and therefore their responses are poor.
In conclusion, 131 I-Lipiodol bound to cytoplasmic membrane of the cancer cell as vesicles of lipids is already at a sufficiently close distance to kill the cancer cells. It is not necessary for the 131 ILipiodol molecules to enter the cancer cell before it can produce its cytotoxicity.
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